Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Large-scale genetic correlation studies explore the causal relationship and potential mechanism between gut microbiota and COVID-19-associated risks.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100966981 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2180 (Electronic) Linking ISSN: 14712180 NLM ISO Abbreviation: BMC Microbiol Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: London : BioMed Central, [2001-
    • الموضوع:
    • نبذة مختصرة :
      Recent observational studies suggest that gut microorganisms are involved in the onset and development of coronavirus disease 2019 (COVID-19), but the potential causal relationship behind them remains unclear. Exposure data were derived from the MiBioGen consortium, encompassing 211 gut microbiota (n = 18,340). The outcome data were sourced from the COVID-19 host genetics initiative (round 7), including COVID-19 severity (n = 1,086,211), hospitalization (n = 2,095,324), and susceptibility (n = 2,597,856). First, a two-sample Mendelian randomization (TSMR) was performed to investigate the causal effect between gut microbiota and COVID-19 outcomes. Second, a two-step MR was used to explore the potential mediators and underlying mechanisms. Third, several sensitivity analyses were performed to verify the robustness of the results. Five gut microbes were found to have a potential causality with COVID-19 severity, namely Betaproteobacteria (beta = 0.096, p = 0.034), Christensenellaceae (beta = -0.092, p = 0.023), Adlercreutzia (beta = 0.072, p = 0.048), Coprococcus 1 (beta = 0.089, p = 0.032), Eisenbergiella (beta = 0.064, p = 0.024). Seven gut microbes were found to have a potential causality with COVID-19 hospitalization, namely Victivallaceae (beta = 0.037, p = 0.028), Actinomyces (beta = 0.047, p = 0.046), Coprococcus 2 (beta = -0.061, p = 0.031), Dorea (beta = 0.067, p = 0.016), Peptococcus (beta = -0.035, p = 0.049), Rikenellaceae RC9 gut group (beta = 0.034, p = 0.018), and Proteobacteria (beta = -0.069, p = 0.035). Two gut microbes were found to have a potential causality with COVID-19 susceptibility, namely Holdemanella (beta = -0.024, p = 0.023) and Lachnospiraceae FCS020 group (beta = 0.026, p = 0.027). Multi-omics mediation analyses indicate that numerous plasma proteins, metabolites, and immune factors are critical mediators linking gut microbiota with COVID-19 outcomes. Sensitivity analysis suggested no significant heterogeneity or pleiotropy. These findings revealed the causal correlation and potential mechanism between gut microbiota and COVID-19 outcomes, which may improve our understanding of the gut-lung axis in the etiology and pathology of COVID-19 in the future.
      (© 2024. The Author(s).)
    • References:
      Eur J Epidemiol. 2017 May;32(5):377-389. (PMID: 28527048)
      J Med Virol. 2022 May;94(5):1825-1832. (PMID: 35023191)
      J Agric Food Chem. 2023 Feb 14;:. (PMID: 36786768)
      Annu Rev Genomics Hum Genet. 2018 Aug 31;19:303-327. (PMID: 29709202)
      Nature. 2022 Apr;604(7907):697-707. (PMID: 35255491)
      Crit Care. 2023 Feb 23;27(1):69. (PMID: 36814280)
      Viruses. 2022 Feb 25;14(3):. (PMID: 35336884)
      Int J Syst Evol Microbiol. 2008 May;58(Pt 5):1221-7. (PMID: 18450717)
      Front Immunol. 2023 Dec 07;14:1249017. (PMID: 38146362)
      Gastroenterology. 2023 Feb;164(2):272-288. (PMID: 36155191)
      Nat Rev Microbiol. 2023 Mar;21(3):133-146. (PMID: 36639608)
      Genet Epidemiol. 2016 May;40(4):304-14. (PMID: 27061298)
      Biomedicines. 2022 Nov 02;10(11):. (PMID: 36359311)
      Microbes Infect. 2022 Feb;24(1):104880. (PMID: 34425246)
      Nat Genet. 2023 Jan;55(1):44-53. (PMID: 36635386)
      Nat Genet. 2021 Feb;53(2):156-165. (PMID: 33462485)
      Biomedicines. 2023 Jan 27;11(2):. (PMID: 36830905)
      Innovation (Camb). 2021 Jul 01;2(3):100141. (PMID: 34557778)
      BMJ. 2018 Jul 12;362:k601. (PMID: 30002074)
      Osteoarthritis Cartilage. 2021 Dec;29(12):1741-1750. (PMID: 34425228)
      Front Immunol. 2023 Jan 10;13:1079995. (PMID: 36703980)
      Clin Microbiol Rev. 2015 Apr;28(2):419-42. (PMID: 25788515)
      Med. 2022 Jun 10;3(6):371-387.e9. (PMID: 35434682)
      Gut. 2021 Jul;70(7):1253-1265. (PMID: 33789966)
      J Med Virol. 2022 Nov;94(11):5345-5353. (PMID: 35854470)
      Nat Commun. 2020 Jan 17;11(1):376. (PMID: 31953392)
      Int J Epidemiol. 2019 Jun 1;48(3):728-742. (PMID: 30561657)
      Emerg Infect Dis. 2022 Nov;28(11):2350-2352. (PMID: 36191906)
      Nat Commun. 2019 Aug 9;10(1):3613. (PMID: 31399576)
      Adv Sci (Weinh). 2021 Oct;8(20):e2102785. (PMID: 34423593)
      Nat Commun. 2022 Sep 6;13(1):5235. (PMID: 36068270)
      J Transl Med. 2024 Apr 29;22(1):392. (PMID: 38685026)
      Genome Biol. 2019 Nov 1;20(1):219. (PMID: 31672155)
      Gastroenterology. 2022 Aug;163(2):495-506.e8. (PMID: 35508284)
      Nat Genet. 2020 Oct;52(10):1036-1045. (PMID: 32929287)
      Biochem J. 2017 May 16;474(11):1823-1836. (PMID: 28512250)
      BMJ. 2022 May 18;377:e069676. (PMID: 35584816)
      Int J Epidemiol. 2015 Apr;44(2):512-25. (PMID: 26050253)
      Nat Genet. 2018 May;50(5):693-698. (PMID: 29686387)
      Acta Neuropathol. 2023 Jan;145(1):127-143. (PMID: 36264506)
      Nat Rev Gastroenterol Hepatol. 2023 May;20(5):323-337. (PMID: 36271144)
      Nat Med. 2022 Jul;28(7):1461-1467. (PMID: 35614233)
      Nat Commun. 2022 Nov 1;13(1):5926. (PMID: 36319618)
      Front Med. 2022 Apr;16(2):263-275. (PMID: 35258762)
      Cell Host Microbe. 2022 Nov 9;30(11):1615-1629.e5. (PMID: 36323315)
      BMC Microbiol. 2018 Nov 16;18(1):188. (PMID: 30445918)
      World J Gastroenterol. 2022 Oct 28;28(40):5801-5806. (PMID: 36353201)
      Sci Rep. 2021 Oct 29;11(1):21297. (PMID: 34716394)
      Gastroenterology. 2020 Sep;159(3):944-955.e8. (PMID: 32442562)
      Am J Respir Crit Care Med. 2021 Dec 15;204(12):1379-1390. (PMID: 34534435)
      PLoS Genet. 2017 Nov 17;13(11):e1007081. (PMID: 29149188)
      Clin Infect Dis. 2020 Dec 17;71(10):2669-2678. (PMID: 32497191)
      Gut. 2021 Apr;70(4):698-706. (PMID: 33431578)
      Nat Med. 2022 Mar;28(3):583-590. (PMID: 35132265)
      Gut. 2021 Feb;70(2):276-284. (PMID: 32690600)
      Microbiome. 2023 Mar 3;11(1):38. (PMID: 36869345)
      Bioinformatics. 2015 Feb 15;31(4):608-9. (PMID: 25677125)
      Nat Genet. 2019 Apr;51(4):600-605. (PMID: 30778224)
      Nat Rev Methods Primers. 2022 Feb 10;2:. (PMID: 37325194)
      Nat Genet. 2021 Dec;53(12):1712-1721. (PMID: 34857953)
      Antibiotics (Basel). 2023 Mar 02;12(3):. (PMID: 36978365)
      Microbiome. 2022 Oct 5;10(1):165. (PMID: 36195943)
    • Contributed Indexing:
      Keywords: COVID-19; Gut microbiota; Mediation analysis; Mendelian randomization
    • الموضوع:
      Date Created: 20240805 Date Completed: 20240806 Latest Revision: 20240808
    • الموضوع:
      20240808
    • الرقم المعرف:
      PMC11299294
    • الرقم المعرف:
      10.1186/s12866-024-03423-0
    • الرقم المعرف:
      39103761